

**Decisions by  
Extraordinary General Meetings of Shareholders**

The Extraordinary General Meetings of Shareholders of Antibiotice S.A. Iași, a trading company established and operating according to the Romanian law, registered at the Trade Register Office Iasi attached to the Court of Iasi, under the no. J22/285/1991, unique registration code RO1973096, headquartered in 1 Valea Lupului St., Iasi, Romania, having subscribed and paid-up capital in the amount of 67,133,804 LEI divided in 671,338,040 registered shares, with a nominal value of 0.10 lei each,

*convened* by the announcement published in the Official Gazette of Romania, Part IV, no. 4140 dated 18.09.2023 and in Evenimentul no. 9885 dated 19.09.2023,

according to the provisions of Law no. 31/1990 on trading companies, republished, with the subsequent amendments and completions, Law no. 24/2017, Financial Supervisory Authority (ASF) Regulation no. 5/2018 on issuers of financial instruments and market operations, Law no. 111/2016 for the approval of the Government Emergency Ordinance no. 109/2011 on corporate governance of public enterprises and provisions of the company's Articles of Association,

*reunited* on 30.10.2023 at 10 AM for an Extraordinary Meeting of Shareholders, for the first reunion, gathering shareholders that represent \_\_\_\_\_% of the share capital,

**DECIDES :**

**I.      *Extraordinary General Meeting of Shareholders***

**Decision no. 1:** With the vote of the shareholders representing \_\_\_\_\_% of the share capital value and \_\_\_\_\_% of the total votes cast, the GMS approves the signing with the European Investment Bank of the 25,000,000 euro financing contract, i.e. 123,005,000 lei, calculated at a rate of 4.9202 lei/euro, of which:

- 115,098,845 lei for co-financing the investment objective "Production, packaging and storage capacity for sterile products, solutions and topicals" which is the subject of Financing Agreement no. 538/17.05.2023 of the Ministry of Finance;
- 7,906,155 lei for financing the investments included in "The Future Together" Business Plan.

**Decision no. 2:** With the vote of the shareholders representing \_\_\_\_\_% of the share capital value and \_\_\_\_\_% of the total votes cast, the GMS approves the negotiation and signing of any other documents in connection with the financing contract including, without limitation, any withdrawal requests and any addenda or supplementary documents or other documents related to the financing documents.

**Decision no. 3:** With the vote of the shareholders representing \_\_\_\_\_% of the share capital value and \_\_\_\_\_% of the total votes cast, the GMS approves to empower the General Director:

- a. to negotiate and sign on behalf of the company the credit contract, addenda and any other related documents according to the above-mentioned items;
- b. to undertake all and any necessary or useful actions and things in the interest of Antibiotice S.A. with the aim of carrying out the above-mentioned operations;
- c. to subdelegate, in compliance with the applicable legal provisions, all or any of the above duties, by appointing and revoking any substitutes and agents with regard to all or any of the previously provided powers and aspects, as he deems appropriate, the respective substitutes and agents having the authority to act on behalf Antibiotice S.A.

These decisions are signed today, 30/31.10.2023, at the company headquarters in 2 original copies.

Representative of the Public Guardianship Authority,

\_\_\_\_\_  
authorized by mandate no. \_\_\_\_\_

President of the Management Board,  
***Lucian TIMOFTICIUC***